The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
Irreversible Electroporation Therapy in the Management of Locally Advanced Pancreatic Adenocarcinoma
Abstract
BACKGROUND: Locally advanced pancreatic cancer patients have limited options for disease control. Local ablation technologies based on thermal damage have been used but are associated with major complications in this region of the pancreas. Irreversible electroporation (IRE) is a nonthermal ablation technology that we have shown is safe near vital vascular and ductal structures. The aim of this study was to evaluate the safety and efficacy of IRE as a therapy in the treatment of locally advanced pancreatic cancer. STUDY DESIGN: We performed a prospective multi-institutional pilot evaluation of patients undergoing IRE for locally advanced pancreatic cancer from December 2009 to March 2011. These patients were evaluated for 90-day morbidity, mortality, and local disease control. RESULTS: Twenty-seven patients (13 women and 14 men) underwent IRE, with median age of 61 years (range 45 to 80 years). Eight patients underwent margin accentuation with IRE in combination with left-sided resection (n = 4) or pancreatic head resection (n = 4). Nineteen patients had in situ IRE. All patients underwent successful IRE, with intraoperative imaging confirming effective delivery of therapy. All 27 patients demonstrated nonclinically relevant elevation of their amylase and lipase, which peaked at 48 hours and returned to normal at 72 hour postprocedure. There has been one 90-day mortality. No patient has shown evidence of clinical pancreatitis or fistula formation. After all patients have completed 90-day follow-up, there has been 100% ablation success. CONCLUSIONS: IRE ablation of locally advanced pancreatic cancer tumors is a safe and feasible primary local treatment in unresectable, locally advanced disease. Confirming these early results must occur in a planned phase II investigational device exemption (IDE) study to be initiated in 2012.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Jemal, A., Bray, F., Center, M. M., Ferlay, J., Ward, E., & Forman, D. (2011) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20107 · Cited by 54,679
(2017) · Springer eBooks · doi:10.1007/978-3-319-40618-3 · Cited by 17,242
Gene transfer into mouse lyoma cells by electroporation in high electric fields.
Neumann, E., Schaefer-Ridder, M., Wang, Y., & Hofschneider, P. H. (1982) · The EMBO Journal · doi:10.1002/j.1460-2075.1982.tb01257.x · Cited by 2,502
Callery, M. P., Chang, K. J., Fishman, E. K., Talamonti, M. S., William Traverso, L., & Linehan, D. C. (2009) · Annals of Surgical Oncology · doi:10.1245/s10434-009-0408-6 · Cited by 902
Borderline Resectable Pancreatic Cancer: Definitions, Management, and Role of Preoperative Therapy
Varadhachary, G. R., Tamm, E. P., Abbruzzese, J. L., Xiong, H. Q., Crane, C. H., Wang, H., Lee, J. E., Pisters, P. W. T., Evans, D. B., & Wolff, R. A. (2006) · Annals of Surgical Oncology · doi:10.1245/aso.2006.08.011 · Cited by 876
Loehrer, P. J., Feng, Y., Cardenes, H., Wagner, L., Brell, J. M., Cella, D., Flynn, P., Ramanathan, R. K., Crane, C. H., Alberts, S. R., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.34.8904 · Cited by 830
Chauffert, B., Mornex, F., Bonnetain, F., Rougier, P., Mariette, C., Bouché, O., Bosset, J. F., Aparicio, T., Mineur, L., Azzedine, A., et al. (2008) · Annals of Oncology · doi:10.1093/annonc/mdn281 · Cited by 696
Urdaneta, A. B. (1972) · PubMed · Cited by 632
Teissie, J., Golzio, M., & Rols, M. P. (2005) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2005.05.006 · Cited by 622
Espey, D. K., Wu, X., Swan, J., Wiggins, C., Jim, M. A., Ward, E., Wingo, P. A., Howe, H. L., Ries, L. A. G., Miller, B. A., et al. (2007) · Cancer · doi:10.1002/cncr.23044 · Cited by 576
Cited by
Electroporation-Based Technologies for Medicine: Principles, Applications, and Challenges
Yarmush, M. L., Golberg, A., Serša, G., Kotnik, T., & Miklavčič, D. (2014) · Annual Review of Biomedical Engineering · doi:10.1146/annurev-bioeng-071813-104622 · Cited by 889
Scheffer, H. J., Nielsen, K., de Jong, M. C., van Tilborg, A. A. J. M., Vieveen, J. M., Bouwman, A. (. A. )., Meijer, S., van Kuijk, C., van den Tol, P. (. P. )., & Meijerink, M. R. (2014) · Journal of Vascular and Interventional Radiology · doi:10.1016/j.jvir.2014.01.028 · Cited by 421
Martin, R. C. G., Kwon, D., Chalikonda, S., Sellers, M., Kotz, E., Scoggins, C., McMasters, K. M., & Watkins, K. (2015) · Annals of Surgery · doi:10.1097/sla.0000000000001441 · Cited by 417
Self-citationPhase I/II study of verteporfin photodynamic therapy in locally advanced pancreatic cancer
Huggett, M. T., Jermyn, M., Gillams, A., Illing, R., Mosse, S., Novelli, M., Kent, E., Bown, S. G., Hasan, T., Pogue, B. W., et al. (2014) · British Journal of Cancer · doi:10.1038/bjc.2014.95 · Cited by 396
Pancreatic Cancer: A Review of Current Treatment and Novel Therapies
Kolbeinsson, H. M., Chandana, S., Wright, G. P., & Chung, M. (2023) · Journal of Investigative Surgery · doi:10.1080/08941939.2022.2129884 · Cited by 386
Tumor Ablation: Common Modalities and General Practices
Knavel, E. M., & Brace, C. L. (2013) · Techniques in Vascular and Interventional Radiology · doi:10.1053/j.tvir.2013.08.002 · Cited by 368
A Review of Basic to Clinical Studies of Irreversible Electroporation Therapy
Jiang, C., Davalos, R. V., & Bischof, J. C. (2015) · IEEE Transactions on Biomedical Engineering · doi:10.1109/tbme.2014.2367543 · Cited by 332
Martin, R. C. G., McFarland, K., Ellis, S., & Velanovich, V. (2013) · Annals of Surgical Oncology · doi:10.1245/s10434-012-2736-1 · Cited by 306
Self-citationIrreversible electroporation (NanoKnife) in cancer treatment
Jourabchi, N., Beroukhim, K., Tafti, B. A., Kee, S. T., & Lee, E. W. (2014) · Gastrointestinal Intervention · doi:10.1016/j.gii.2014.02.002 · Cited by 99
Present and future of metal nanoparticles in tumor ablation therapy
Lou, W., Xie, L., Xu, L., Xu, M., Xu, F., Zhao, Q., & Jiang, T. (2023) · Nanoscale · doi:10.1039/d3nr04362b · Cited by 33
Metadata
- Authors
- Martin, R. C. G., McFarland, K., Ellis, S., & Velanovich, V.
- Venue
- Journal of the American College of Surgeons
- Published
- 2012-09
- Volume
- 215
- Issue
- 3
- Pages
- 361-369
- ISSN
- 1072-7515 (ISSN-L)
- OpenAlex
- W1985367511
- Cited by
- 287
- References
- 33
- FWCI
- 12.07
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.